8.32
+2.455(+41.89%)
Currency In USD
| Previous Close | 5.86 |
| Open | 7.21 |
| Day High | 8.49 |
| Day Low | 7.19 |
| 52-Week High | 11.41 |
| 52-Week Low | 3.03 |
| Volume | 27.42M |
| Average Volume | 516,303 |
| Market Cap | 266.23M |
| PE | -5.26 |
| EPS | -1.58 |
| Moving Average 50 Days | 5.43 |
| Moving Average 200 Days | 6.82 |
| Change | 2.46 |
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 05, 2026 12:00 PM GMT
SAN MATEO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that man
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
GlobeNewswire Inc.
Feb 02, 2026 12:00 PM GMT
SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Asc
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it